Close Menu

NEW YORK (GenomeWeb News) — Transposagen Biopharmaceuticals said today that it has expanded its license for DNA transposon technology to cover nearly all commercial applications, including as a tool for drug and biomarker discovery.

The intellectual property for the transposon technology, called piggyBac, is jointly owned by the University of Notre Dame, the University of Florida, and the US Department of Agriculture.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The UK is investing £33.6 million into a controversial human SARS-CoV-2 challenge study, according to Reuters.

The Guardian reports that the UK COVID genomics consortium is monitoring mutations that are arising within circulating SARS-CoV-2 strains for any that may affect future vaccines.

Science reports that Max Planck and Nature have struck a deal for affiliated authors to publish papers that are accessible to the public as well as access Nature-branded journals.

In PNAS this week: genomic analysis of ancient animals from Tibet, oncoproteins tied to WEE1 kinase enzyme inhibitor response, and more.